

**Contact**

Merck KGaA, Darmstadt, Germany

Investor Relations

Frankfurter Strasse 250

64293 Darmstadt

Germany

Phone: +49 6151 72 3321

e-mail: [investor.relations@emdgroup.com](mailto:investor.relations@emdgroup.com)

[www.emdgroup.com](http://www.emdgroup.com)

WKN: 659990

ISIN: DE0006599905

Ticker Symbol: MRK

## Financial Statements Q1 2022 – Q3 2023

**Content**

---

**1 Income statements**

- 1.1 Group, quarterly
- 1.2 Life Science, quarterly
- 1.3 Healthcare, quarterly
- 1.4 Electronics, quarterly
- 1.5 Corporate/Others, quarterly
- 1.6 Financial result, quarterly

**2 Cash flow statement****3 Balance sheet**



Income Statement Merck KGaA, Darmstadt, Germany

Group € million	2022								2023								Change YoY							
	Q1	Q2	H1	Q3	9M	Q4	H2	FY	Q1	Q2	H1	Q3	9M	Q4	H2	FY	Q1	Q2	H1	Q3	9M	Q4	H2	FY
<b>Net sales</b>	<b>5,197.8</b>	<b>5,568.4</b>	<b>10,766.2</b>	<b>5,805.7</b>	<b>16,571.9</b>	<b>5,660.4</b>	<b>11,466.1</b>	<b>22,232.3</b>	<b>5,293.0</b>	<b>5,302.4</b>	<b>10,595.3</b>	<b>5,173.1</b>	<b>15,768.4</b>				1.8%	-4.8%	-1.6%	-10.9%	-4.8%			
Cost of sales	-1,987.0	-2,108.6	-4,095.6	-2,147.5	-6,243.1	-2,284.2	-4,431.6	-8,527.3	-1,972.5	-2,138.9	-4,111.4	-2,161.8	-6,273.2				-0.7%	1.4%	0.4%	0.7%	0.5%			
thereof amortization of intangible assets	-50.3	-53.2	-103.6	-52.3	-155.9	-51.3	-103.6	-207.1	-48.2	-46.2	-94.3	-40.3	-134.7				-4.3%	-13.3%	-8.9%	-22.9%	-13.6%			
Gross profit	3,210.8	3,459.8	6,670.5	3,658.2	10,328.8	3,376.2	7,034.4	13,705.0	3,320.4	3,163.5	6,483.9	3,011.3	9,495.2				3.4%	-8.6%	-2.8%	-17.7%	-8.1%			
<i>in % of net sales</i>	61.8%	62.1%	62.0%	63.0%	62.3%	59.6%	61.4%	61.6%	62.7%	59.7%	61.2%	58.2%	60.2%											
SG&A	-1,451.8	-1,683.1	-3,135.0	-1,782.4	-4,917.3	-1,793.0	-3,575.3	-6,710.3	-1,688.2	-1,593.6	-3,281.8	-1,447.0	-4,728.8				16.3%	-5.3%	4.7%	-18.8%	-3.8%			
<i>in % of net sales</i>	27.9%	30.2%	29.1%	30.7%	29.7%	31.7%	31.2%	30.2%	31.9%	30.1%	31.0%	28.0%	30.0%											
Marketing and selling expenses	-1,087.2	-1,193.6	-2,280.8	-1,223.5	-3,504.3	-1,209.4	-2,432.9	-4,713.7	-1,109.1	-1,139.4	-2,248.5	-1,104.3	-3,352.9				2.0%	-4.5%	-1.4%	-9.7%	-4.3%			
thereof amortization of intangible assets (M&S)	-144.8	-153.7	-298.5	-159.9	-458.4	-158.1	-317.9	-616.4	-151.3	-148.9	-300.2	-146.7	-446.9				4.5%	-3.1%	0.6%	-8.2%	-2.5%			
Administration expenses	-287.2	-330.5	-617.7	-327.9	-945.7	-360.8	-688.7	-1,306.4	-357.9	-345.0	-702.9	-312.0	-1,014.9				24.6%	4.4%	13.8%	-4.9%	7.3%			
Impairment losses and reversals (IFRS 9)	-5.0	-8.7	-13.6	6.2	-7.4	1.9	8.1	-5.5	-2.2	-9.7	-11.9	-28.3	-40.2				-56.3%	12.3%	-12.7%	n.m.	443.2%			
Other operating expenses/income	-72.4	-150.4	-222.8	-237.2	-460.0	-224.6	-461.8	-684.6	-219.0	-99.4	-318.4	-2.3	-320.8				202.3%	-33.9%	42.9%	-99.0%	-30.3%			
Impairments**	-2.6	-90.0	-92.6	-10.9	-103.5	-128.4	-139.3	-231.9	-9.7	-36.9	-46.6	-3.8	-50.4				271.0%	-59.0%	-49.7%	-65.2%	-51.3%			
Research and development costs	-585.5	-599.6	-1,185.1	-641.7	-1,826.8	-693.7	-1,335.4	-2,520.5	-597.3	-600.4	-1,197.7	-581.1	-1,778.8				2.0%	0.1%	1.1%	-9.4%	-2.6%			
<i>in % of net sales</i>	11.3%	10.8%	11.0%	11.1%	11.0%	12.3%	11.6%	11.3%	11.3%	11.3%	11.3%	11.2%	11.3%											
thereof amortization of intangible assets (R&D)	-1.7	-1.7	-3.4	-1.6	-5.0	-1.7	-3.3	-6.7	-4.4	-3.0	-7.4	-3.2	-10.6				165.5%	75.1%	119.5%	98.8%	112.8%			
<b>EBIT</b>	<b>1,173.4</b>	<b>1,177.0</b>	<b>2,350.4</b>	<b>1,234.2</b>	<b>3,584.6</b>	<b>889.6</b>	<b>2,123.7</b>	<b>4,474.2</b>	<b>1,035.0</b>	<b>969.5</b>	<b>2,004.4</b>	<b>983.2</b>	<b>2,987.7</b>				-11.8%	-17.6%	-14.7%	-20.3%	-16.7%			
<i>in % of net sales</i>	22.6%	21.1%	21.8%	21.3%	21.6%	15.7%	18.5%	20.1%	19.6%	18.3%	18.9%	19.0%	18.9%											
Depreciation and amortization	429.6	532.3	961.9	469.7	1,431.6	598.5	1,068.2	2,030.1	455.5	482.3	937.8	435.2	1,373.0				6.0%	-9.4%	-2.5%	-7.3%	-4.1%			
<b>EBITDA</b>	<b>1,603.0</b>	<b>1,709.4</b>	<b>3,312.3</b>	<b>1,703.9</b>	<b>5,016.2</b>	<b>1,488.1</b>	<b>3,191.9</b>	<b>6,504.3</b>	<b>1,490.5</b>	<b>1,451.8</b>	<b>2,942.3</b>	<b>1,418.4</b>	<b>4,360.7</b>				-7.0%	-15.1%	-11.2%	-16.8%	-13.1%			
<i>in % of net sales</i>	30.8%	30.7%	30.8%	29.3%	30.3%	26.3%	27.8%	29.3%	28.2%	27.4%	27.8%	27.4%	27.7%											
<b>EBITDA pre</b>	<b>1,628.8</b>	<b>1,782.0</b>	<b>3,410.8</b>	<b>1,810.5</b>	<b>5,221.2</b>	<b>1,627.9</b>	<b>3,438.4</b>	<b>6,849.1</b>	<b>1,587.0</b>	<b>1,553.3</b>	<b>3,140.3</b>	<b>1,445.6</b>	<b>4,585.9</b>				-2.6%	-12.8%	-7.9%	-20.2%	-12.2%			
<i>in % of net sales</i>	31.3%	32.0%	31.7%	31.2%	31.5%	28.8%	30.0%	30.8%	30.0%	29.3%	29.6%	27.9%	29.1%											
Financial result	-34.3	-55.1	-89.4	-47.0	-136.4	-50.5	-97.5	-186.9	-22.7	-75.7	-98.4	-46.0	-144.3				-33.9%	37.4%	10.0%	-2.3%	5.8%			
Profit before income tax from continuing operations	1,139.1	1,122.0	2,261.0	1,187.2	3,448.2	839.1	2,026.2	4,287.3	1,012.3	893.8	1,906.1	937.3	2,843.3				-11.1%	-20.3%	-15.7%	-21.1%	-17.5%			
Income tax	-255.4	-251.7	-507.1	-261.2	-768.3	-179.7	-440.9	-948.0	-212.6	-187.7	-400.3	-196.8	-597.1				-16.8%	-25.4%	-21.1%	-24.6%	-22.3%			
<i>Income tax rate</i>	22.4%	22.4%	22.4%	22.0%	22.3%	21.4%	21.8%	22.1%	21.0%	21.0%	21.0%	21.0%	21.0%											
Profit after tax from continuing operations	883.7	870.2	1,754.0	926.0	2,679.9	659.3	1,585.3	3,339.3	799.7	706.1	1,505.8	740.4	2,246.2				-9.5%	-18.9%	-14.1%	-20.0%	-16.2%			
Profit after tax from discontinued operations	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0				n.m.	n.m.	n.m.	n.m.	n.m.			
Profit after tax	883.7	870.2	1,754.0	926.0	2,679.9	659.3	1,585.3	3,339.3	799.7	706.1	1,505.8	740.4	2,246.2				-9.5%	-18.9%	-14.1%	-20.0%	-16.2%			
<b>of which: attributable to Merck KGaA shareholders (ne of which: attributable to non-controlling interests)</b>	<b>880.4</b>	<b>867.1</b>	<b>1,747.5</b>	<b>923.2</b>	<b>2,670.7</b>	<b>655.0</b>	<b>1,578.1</b>	<b>3,325.7</b>	<b>796.2</b>	<b>703.6</b>	<b>1,499.8</b>	<b>738.7</b>	<b>2,238.4</b>				-9.6%	-18.9%	-14.2%	-20.0%	-16.2%			
	3.3	3.1	6.4	2.8	9.2	4.4	7.2	13.6	3.5	2.5	6.0	1.8	7.8				6.3%	-19.2%	-6.1%	-36.6%	-15.3%			
<b>EPS in €</b>	<b>2.02</b>	<b>1.99</b>	<b>4.02</b>	<b>2.12</b>	<b>6.14</b>	<b>1.51</b>	<b>3.63</b>	<b>7.65</b>	<b>1.83</b>	<b>1.62</b>	<b>3.45</b>	<b>1.70</b>	<b>5.15</b>				-9.4%	-18.6%	-14.2%	-19.8%	-16.1%			
thereof from continuing operations	2.02	1.99	4.02	2.12	6.14	1.51	3.63	7.7	1.83	1.62	3.45	1.70	5.15				-9.4%	-18.6%	-14.2%	-19.8%	-16.1%			
thereof from discontinued operations	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.0	0.00	0.00	0.00	0.00	0.00				n.m.	n.m.	n.m.	n.m.	n.m.			
<b>EPS pre in €*</b>	<b>2.41</b>	<b>2.64</b>	<b>5.05</b>	<b>2.68</b>	<b>7.73</b>	<b>2.32</b>	<b>5.01</b>	<b>10.05</b>	<b>2.36</b>	<b>2.20</b>	<b>4.57</b>	<b>2.07</b>	<b>6.64</b>				-2.1%	-16.7%	-9.5%	-22.8%	-14.1%			
<b>Number of theoretical shares in million</b>	<b>434.8</b>	<b>434.8</b>	<b>434.8</b>	<b>434.8</b>	<b>434.8</b>	<b>434.8</b>	<b>434.8</b>	<b>434.8</b>	<b>434.8</b>	<b>434.8</b>	<b>434.8</b>	<b>434.8</b>	<b>434.8</b>											
<b>Reconciliation to EBITDA pre</b>																								
EBITDA	1,603.0	1,709.4	3,312.3	1,703.9	5,016.2	1,488.1	3,191.9	6,504.3	1,490.5	1,451.8	2,942.3	1,418.4	4,360.7				-7.0%	-15.1%	-11.2%	-16.8%	-13.1%			
<b>Adjustments</b>																								
thereof: Cost of Sales	1.6	7.8	9.4	6.0	15.4	16.2	22.2	31.6	2.7	4.6	7.2	10.4	17.6				69.6%	-41.6%	-23.0%	73.3%	14.5%			
thereof: Marketing and selling expenses	0.5	14.0	14.6	6.4	21.0	11.3	17.7	32.3	-0.9	5.4	4.5	8.0	12.4				n.m.	-61.9%	-69.2%	24.5%	-40.7%			
thereof: Administration expenses	19.6	29.7	49.3	31.4	80.7	34.4	65.7	115.1	71.7	41.9	113.6	33.9	147.5				264.8%	41.3%	130.3%	8.1%	82.8%			
thereof: Other operating expenses/income	3.0	14.8	17.7	40.7	58.5	33.0	73.7	91.4	30.9	42.1	73.0	-25.5	47.5				>1.000%	184.9%	311.5%	n.m.	-18.8%			
thereof: Research and development	1.1	6.3	7.4	22.1	29.5	45.0	67.1	74.5	-7.9	7.6	-0.3	0.5	0.1				n.m.	19.4%	n.m.	-97.9%	-99.6%			
<b>Total</b>	<b>25.8</b>	<b>72.6</b>	<b>98.4</b>	<b>106.6</b>	<b>205.0</b>	<b>139.8</b>	<b>246.4</b>	<b>344.9</b>	<b>96.5</b>	<b>101.5</b>	<b>198.0</b>	<b>27.2</b>	<b>225.2</b>				274.1%	39.7%	101.1%	-74.5%	9.8%			
<b>EBITDA pre</b>	<b>1,628.8</b>	<b>1,782.0</b>	<b>3,410.8</b>	<b>1,810.5</b>	<b>5,221.2</b>	<b>1,627.9</b>	<b>3,438.4</b>	<b>6,849.1</b>	<b>1,587.0</b>	<b>1,553.3</b>	<b>3,140.3</b>	<b>1,445.6</b>	<b>4,585.9</b>				-2.6%	-12.8%	-7.9%	-20.2%	-12.2%			

Due to rounding the sum of individual values may not add up to totals presented.

\* For continuing operations.

\*\* Only reflects impairments classified as adjustments.



**Breakdown of depreciation and amortization and adjustments**

Group	Division	2022								2023								Change YoY													
		Q1	Q2	H1	Q3	9M	Q4	H2	FY	Q1	Q2	H1	Q3	9M	Q4	H2	FY	Q1	Q2	H1	Q3	9M	Q4	H2	FY						
<b>a) Depreciation and amortization</b>																															
<b>Regular depreciation and amortization*</b>		all	230.2	233.7	463.9	245.0	708.9	258.9	503.9	967.8	242.0	243.2	485.2	241.1	726.3			5.1%	4.0%	4.6%	-1.6%	2.5%									
<b>Impairments not adjusted</b>		all	0.0	0.0	0.0	0.0	0.0	0.2	0.2	0.2	0.0	4.2	4.2	0.0	4.2			n.m.	n.m.	n.m.	-100.0%	>1.000%									
<b>Amortization of purchased intangible assets</b>																															
Life Science	LS	109.9	121.1	231.0	123.5	354.4	123.5	246.9	477.9	118.2	115.8	234.0	108.5	342.5			7.5%	-4.3%	1.3%	-12.1%	-3.4%										
Healthcare	HC	1.4	1.3	2.8	1.3	4.0	0.3	1.5	4.3	1.5	1.6	3.2	1.7	4.8			8.5%	20.9%	14.5%	31.7%	19.9%										
Electronics	EL	85.4	86.3	171.7	89.0	260.7	87.3	176.3	348.0	84.1	80.6	164.7	80.1	244.8			-1.6%	-6.5%	-4.1%	-10.1%	-6.1%										
<b>Total</b>		<b>196.8</b>	<b>208.7</b>	<b>405.4</b>	<b>213.8</b>	<b>619.2</b>	<b>211.0</b>	<b>424.8</b>	<b>830.2</b>	<b>203.8</b>	<b>198.1</b>	<b>401.9</b>	<b>190.3</b>	<b>592.2</b>			3.6%	-5.1%	-0.9%	-11.0%	-4.4%										
<b>Impairments (net)**</b>		all	2.6	90.0	92.6	10.9	103.5	128.4	139.3	231.9	9.7	36.9	46.6	3.8	50.4			271.0%	-59.0%	-49.7%	-65.2%	-51.3%									
<b>Total depreciation and amortization</b>			<b>429.6</b>	<b>532.3</b>	<b>961.9</b>	<b>469.7</b>	<b>1,431.6</b>	<b>598.5</b>	<b>1,068.2</b>	<b>2,030.1</b>	<b>455.5</b>	<b>482.3</b>	<b>937.8</b>	<b>435.2</b>	<b>1,373.0</b>			6.0%	-9.4%	-2.5%	-7.3%	-4.1%									
<b>b) Adjustments</b>																															
<b>Acquisition costs</b>			1.5	8.6	10.1	7.3	17.4	11.6	18.8	28.9	9.2	4.8	14.0	3.7	17.7			494.7%	-43.8%	38.6%	-49.7%	1.7%									
<b>Restructuring costs</b>																															
Life Science	LS	-3.1	13.1	10.0	28.3	38.2	2.3	30.6	40.6	0.4	1.8	2.2	4.3	6.5			n.m.	-85.9%	-77.5%	-84.9%	-82.9%										
Healthcare	HC	1.9	8.3	10.2	24.5	34.7	56.3	80.7	91.0	-7.3	12.0	4.7	2.6	7.3			n.m.	44.8%	-54.0%	-89.3%	-78.9%										
Electronics	EL	4.7	8.5	13.1	3.4	16.6	14.0	17.4	30.6	2.2	6.9	9.1	9.9	18.9			-53.7%	-18.4%	-30.9%	189.6%	14.5%										
Corporate and Other	CO	4.8	7.9	12.8	7.0	19.8	16.5	23.5	36.3	49.0	18.5	67.6	7.9	75.4			>1.000%	133.6%	429.4%	12.2%	281.6%										
<b>Total</b>		<b>8.3</b>	<b>37.8</b>	<b>46.1</b>	<b>63.1</b>	<b>109.2</b>	<b>89.2</b>	<b>152.3</b>	<b>198.4</b>	<b>44.3</b>	<b>39.3</b>	<b>83.6</b>	<b>24.6</b>	<b>108.2</b>			431.4%	4.1%	81.3%	-61.0%	-0.9%										
<b>Integration costs/IT costs</b>																															
Integration Cost	LS/EL/CO	5.0	2.2	7.1	-2.1	5.0	4.2	2.1	9.2	1.9	2.0	4.0	2.2	6.1			-61.2%	-5.1%	-44.2%	n.m.	21.9%										
ERP/HR systems	all	15.0	22.0	37.0	24.8	61.9	16.4	41.3	78.3	21.6	25.0	46.6	26.7	73.2			43.7%	13.6%	25.8%	7.4%	18.4%										
<b>Total</b>		<b>20.0</b>	<b>24.2</b>	<b>44.1</b>	<b>22.7</b>	<b>66.9</b>	<b>20.7</b>	<b>43.4</b>	<b>87.5</b>	<b>23.5</b>	<b>27.1</b>	<b>50.6</b>	<b>28.8</b>	<b>79.4</b>			17.7%	12.0%	14.5%	26.7%	18.7%										
<b>Gain (-)/ losses (+) on the divestment of businesses</b>																															
Costs related to former business activities	CO	-10.3	-11.5	-21.8	-4.1	-25.9	3.2	-0.9	-22.7	0.0	21.0	21.0	-3.0	18.0			-100.0%	n.m.	n.m.	-26.6%	n.m.										
Costs related to former business activities	EL	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0			n.m.	n.m.	n.m.	n.m.	n.m.										
Sale of CH, Allergopharma and others	HC	0.0	-10.1	-10.1	0.0	-10.1	-4.7	-4.7	-14.8	0.3	-3.9	-3.6	-45.8	-49.4			n.m.	-61.5%	-64.5%	n.m.	387.9%										
Costs related to former business activities	LS	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0			n.m.	n.m.	n.m.	n.m.	n.m.										
<b>Total</b>		<b>-10.3</b>	<b>-21.6</b>	<b>-31.9</b>	<b>-4.1</b>	<b>-36.0</b>	<b>-1.5</b>	<b>-5.6</b>	<b>-37.5</b>	<b>0.3</b>	<b>17.1</b>	<b>17.4</b>	<b>-48.8</b>	<b>-31.4</b>			n.m.	n.m.	n.m.	>1.000%	-12.9%										
<b>Other one-time costs</b>																															
Others	HC	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0			-100.0%	n.m.	-100.0%	n.m.	-100.0%										
	LS	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0			n.m.	n.m.	n.m.	n.m.	n.m.										
	EL	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0			n.m.	n.m.	n.m.	n.m.	n.m.										
	CO	6.2	23.8	30.0	17.5	47.5	20.0	37.5	67.5	19.2	13.2	32.4	18.9	51.3			208.4%	-44.5%	8.0%	7.8%	7.9%										
<b>Total</b>		<b>6.2</b>	<b>23.8</b>	<b>30.0</b>	<b>17.5</b>	<b>47.5</b>	<b>20.0</b>	<b>37.5</b>	<b>67.5</b>	<b>19.2</b>	<b>13.2</b>	<b>32.4</b>	<b>18.9</b>	<b>51.3</b>			208.4%	-44.5%	8.0%	7.8%	7.9%										
<b>Total adjustments</b>			<b>25.8</b>	<b>72.6</b>	<b>98.4</b>	<b>106.6</b>	<b>205.0</b>	<b>139.8</b>	<b>246.4</b>	<b>344.9</b>	<b>96.5</b>	<b>101.5</b>	<b>198.0</b>	<b>27.2</b>	<b>225.2</b>			274.1%	39.7%	101.1%	-74.5%	9.8%									

Due to rounding the sum of individual values may not add up to totals presented.

\* Regular depreciation and amortization = Depreciation and amortization - Amortization of purchased intangible assets - Impairments

\*\* Only reflects impairments classified as adjustments.

Income Statement Merck KGaA, Darmstadt, Germany

Life Science

€ million

	2022									2023						Change YoY								
	Q1	Q2	H1	Q3	9M	Q4	H2	FY	Q1	Q2	H1	Q3	9M	Q4	H2	FY	Q1	Q2	H1	Q3	9M	Q4	H2	FY
<b>Net sales</b>	<b>2,445.4</b>	<b>2,647.8</b>	<b>5,093.2</b>	<b>2,680.7</b>	<b>7,773.9</b>	<b>2,606.4</b>	<b>5,287.1</b>	<b>10,380.3</b>	<b>2,486.8</b>	<b>2,353.5</b>	<b>4,840.3</b>	<b>2,190.9</b>	<b>7,031.2</b>				1.7%	-11.1%	-5.0%	-18.3%	-9.6%			
Cost of sales	-965.1	-1,052.3	-2,017.4	-1,070.5	-3,087.9	-1,192.1	-2,262.6	-4,280.0	-999.2	-1,078.2	-2,077.5	-1,031.1	-3,108.6				3.5%	2.5%	3.0%	-3.7%	0.7%			
thereof amortization of intangible assets	-13.5	-16.7	-30.2	-15.2	-45.4	-15.1	-30.2	-60.4	-13.3	-13.5	-26.8	-8.3	-35.1				-1.0%	-19.4%	-11.1%	-45.6%	-22.7%			
Gross profit	1,480.4	1,595.5	3,075.8	1,610.2	4,686.0	1,414.4	3,024.5	6,100.4	1,487.5	1,275.3	2,762.8	1,159.7	3,922.6				0.5%	-20.1%	-10.2%	-28.0%	-16.3%			
<i>in % of net sales</i>	60.5%	60.3%	60.4%	60.1%	60.3%	54.3%	57.2%	58.8%	59.8%	54.2%	57.1%	52.9%	55.8%											
SG&A	-669.0	-731.6	-1,400.5	-785.3	-2,185.8	-707.4	-1,492.6	-2,893.2	-711.3	-720.8	-1,432.2	-673.2	-2,105.4				6.3%	-1.5%	2.3%	-14.3%	-3.7%			
<i>in % of net sales</i>	27.4%	27.6%	27.5%	29.3%	28.1%	27.1%	28.2%	27.9%	28.6%	30.6%	29.6%	30.7%	29.9%											
Marketing and selling expenses	-552.0	-608.8	-1,160.8	-633.9	-1,794.7	-605.4	-1,239.2	-2,400.1	-567.5	-566.3	-1,133.8	-555.7	-1,689.5				2.8%	-7.0%	-2.3%	-12.3%	-5.9%			
thereof amortization of intangible assets (M&S)	-95.6	-103.6	-199.2	-107.5	-306.7	-107.7	-215.2	-414.4	-101.4	-100.4	-201.8	-98.2	-300.0				6.1%	-3.1%	1.3%	-8.7%	-2.2%			
Administration expenses	-91.5	-102.8	-194.2	-112.0	-306.2	-93.4	-205.4	-399.7	-105.0	-102.8	-207.7	-102.7	-310.5				14.8%	0.0%	7.0%	-8.3%	1.4%			
Impairment losses and reversals (IFRS 9)	-1.7	-7.6	-9.3	1.7	-7.7	-0.9	0.8	-8.5	-1.1	-1.2	-2.3	-0.1	-2.4				-37.1%	-83.9%	-75.3%	n.m.	-69.1%			
Other operating expenses/income	-23.8	-12.3	-36.1	-41.1	-77.2	-7.7	-48.8	-84.9	-37.8	-50.6	-88.3	-14.8	-103.1				58.4%	311.0%	144.4%	-64.0%	33.6%			
Impairments**	-1.3	0.0	-1.3	0.0	-1.3	-23.2	-23.2	-24.5	0.0	-31.9	-31.9	0.0	-31.9				-100.0%	>1.000%	>1.000%	-100.0%	>1.000%			
Research and development costs	-88.1	-98.5	-186.7	-105.7	-292.3	-106.8	-212.5	-399.2	-103.8	-99.1	-203.0	-90.4	-293.3				17.8%	0.6%	8.7%	-14.5%	0.3%			
<i>in % of net sales</i>	3.6%	3.7%	3.7%	3.9%	3.8%	4.1%	4.0%	3.8%	4.2%	4.2%	4.2%	4.1%	4.2%											
thereof amortization of intangible assets (R&D)	-0.8	-0.8	-1.6	-0.8	-2.4	-0.7	-1.5	-3.1	-3.4	-2.0	-5.4	-2.1	-7.5				327.5%	153.1%	240.3%	160.9%	213.8%			
<b>EBIT</b>	<b>723.3</b>	<b>765.4</b>	<b>1,488.6</b>	<b>719.2</b>	<b>2,207.9</b>	<b>600.2</b>	<b>1,319.4</b>	<b>2,808.0</b>	<b>672.4</b>	<b>455.3</b>	<b>1,127.7</b>	<b>396.1</b>	<b>1,523.8</b>				-7.0%	-40.5%	-24.2%	-44.9%	-31.0%			
<i>in % of net sales</i>	29.6%	28.9%	29.2%	26.8%	28.4%	23.0%	25.0%	27.1%	27.0%	19.3%	23.3%	18.1%	21.7%											
Depreciation and amortization	198.3	209.9	408.2	216.6	624.9	244.9	461.5	869.7	211.7	243.1	454.8	204.6	659.4				6.7%	15.8%	11.4%	-5.6%	5.5%			
<b>EBITDA</b>	<b>921.6</b>	<b>975.3</b>	<b>1,896.9</b>	<b>935.9</b>	<b>2,832.7</b>	<b>845.0</b>	<b>1,780.9</b>	<b>3,677.8</b>	<b>884.0</b>	<b>698.5</b>	<b>1,582.5</b>	<b>600.7</b>	<b>2,183.3</b>				-4.1%	-28.4%	-16.6%	-35.8%	-22.9%			
<i>in % of net sales</i>	37.7%	36.8%	37.2%	34.9%	36.4%	32.4%	33.7%	35.4%	35.5%	29.7%	32.7%	27.4%	31.1%											
<b>EBITDA pre</b>	<b>927.1</b>	<b>1,005.7</b>	<b>1,932.8</b>	<b>976.4</b>	<b>2,909.2</b>	<b>850.3</b>	<b>1,826.8</b>	<b>3,759.6</b>	<b>900.6</b>	<b>711.9</b>	<b>1,612.5</b>	<b>615.1</b>	<b>2,227.6</b>				-2.9%	-29.2%	-16.6%	-37.0%	-23.4%			
<i>in % of net sales</i>	37.9%	38.0%	37.9%	36.4%	37.4%	32.6%	34.6%	36.2%	36.2%	30.2%	33.3%	28.1%	31.7%											
<b>Reconciliation to EBITDA pre</b>																								
EBITDA	921.6	975.3	1,896.9	935.9	2,832.7	845.0	1,780.9	3,677.8	884.0	698.5	1,582.5	600.7	2,183.3				-4.1%	-28.4%	-16.6%	-35.8%	-22.9%			
<b>Adjustments</b>																								
thereof: Cost of Sales	0.1	3.0	3.1	2.4	5.5	1.2	3.7	6.7	0.2	-0.1	0.1	2.8	3.0				199.6%	n.m.	-95.8%	16.7%	-46.3%			
thereof: Marketing and selling expenses	0.1	11.3	11.4	4.8	16.2	0.3	5.1	16.4	-1.2	0.3	-0.9	0.3	-0.6				n.m.	-97.5%	n.m.	-93.4%	n.m.			
thereof: Administration expenses	7.2	9.0	16.3	10.2	26.4	-4.3	5.9	22.2	11.1	12.0	23.0	9.0	32.0				52.8%	32.7%	41.6%	-11.5%	21.2%			
thereof: Other operating expenses/income	-1.9	7.0	5.0	23.1	28.2	8.4	31.5	36.5	6.4	0.5	6.9	2.3	9.2				n.m.	-93.2%	38.0%	-90.2%	-67.3%			
thereof: Research and development	0.1	0.1	0.2	0.0	0.2	-0.3	-0.3	-0.1	0.0	0.7	0.8	0.0	0.8				-89.3%	554.2%	284.9%	n.m.	268.7%			
<b>Total</b>	<b>5.5</b>	<b>30.4</b>	<b>35.9</b>	<b>40.5</b>	<b>76.5</b>	<b>5.3</b>	<b>45.8</b>	<b>81.8</b>	<b>16.5</b>	<b>13.4</b>	<b>29.9</b>	<b>14.4</b>	<b>44.4</b>				199.6%	-55.9%	-16.7%	-64.4%	-42.0%			
<b>EBITDA pre</b>	<b>927.1</b>	<b>1,005.7</b>	<b>1,932.8</b>	<b>976.4</b>	<b>2,909.2</b>	<b>850.3</b>	<b>1,826.8</b>	<b>3,759.6</b>	<b>900.6</b>	<b>711.9</b>	<b>1,612.5</b>	<b>615.1</b>	<b>2,227.6</b>				-2.9%	-29.2%	-16.6%	-37.0%	-23.4%			

Due to rounding the sum of individual values may not add up to totals presented.

\*\* Only reflects impairments classified as adjustments.

**Detailed reconciliation - Life Science**

€ million	2022								2023						Change YoY												
	Q1	Q2	H1	Q3	9M	Q4	H2	FY	Q1	Q2	H1	Q3	9M	Q4	H2	FY	Q1	Q2	H1	Q3	9M	Q4	H2	FY			
<b>EBIT</b>	<b>723.3</b>	<b>765.4</b>	<b>1,488.6</b>	<b>719.2</b>	<b>2,207.9</b>	<b>600.2</b>	<b>1,319.4</b>	<b>2,808.0</b>	<b>672.4</b>	<b>455.3</b>	<b>1,127.7</b>	<b>396.1</b>	<b>1,523.8</b>				-7.0%	-40.5%	-24.2%	-44.9%	-31.0%						
Regular depreciation and amortization*	87.2	88.8	176.0	93.2	269.2	98.2	191.4	367.4	93.5	95.4	188.9	96.1	285.0				7.3%	7.4%	7.3%	3.1%	5.9%						
Impairments not adjusted	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0				n.m.	n.m.	n.m.	>1.000%	n.m.						
Amortization of purchased intangible assets	109.9	121.1	231.0	123.5	354.4	123.5	246.9	477.9	118.2	115.8	234.0	108.5	342.5				7.5%	-4.3%	1.3%	-12.1%	-3.4%						
Impairments (net)**	1.3	0.0	1.3	0.0	1.3	23.2	23.2	24.5	0.0	31.9	31.9	0.0	31.9				-100.0%	>1.000%	>1.000%	-100.0%	>1.000%						
<b>Total depreciation and amortization</b>	<b>198.3</b>	<b>209.9</b>	<b>408.2</b>	<b>216.6</b>	<b>624.9</b>	<b>244.9</b>	<b>461.5</b>	<b>869.7</b>	<b>211.7</b>	<b>243.1</b>	<b>454.8</b>	<b>204.6</b>	<b>659.4</b>				6.7%	15.8%	11.4%	-5.6%	5.5%						
<b>EBITDA</b>	<b>921.6</b>	<b>975.3</b>	<b>1,896.9</b>	<b>935.9</b>	<b>2,832.7</b>	<b>845.0</b>	<b>1,780.9</b>	<b>3,677.8</b>	<b>884.0</b>	<b>698.5</b>	<b>1,582.5</b>	<b>600.7</b>	<b>2,183.3</b>				-4.1%	-28.4%	-16.6%	-35.8%	-22.9%						
<b>Adjustments</b>																											
<b>Acquisition costs</b>	<b>0.5</b>	<b>7.5</b>	<b>8.0</b>	<b>2.2</b>	<b>10.1</b>	<b>7.4</b>	<b>9.5</b>	<b>17.5</b>	<b>5.0</b>	<b>-0.3</b>	<b>4.8</b>	<b>0.0</b>	<b>4.8</b>				882.2%	n.m.	-39.9%	n.m.	-52.7%						
<b>Restructuring costs</b>																											
Restructuring costs	-3.1	13.1	10.0	28.3	38.2	2.3	30.6	40.6	0.4	1.8	2.2	4.3	6.5				n.m.	-85.9%	-77.5%	-84.9%	-82.9%						
<b>Total</b>	<b>-3.1</b>	<b>13.1</b>	<b>10.0</b>	<b>28.3</b>	<b>38.2</b>	<b>2.3</b>	<b>30.6</b>	<b>40.6</b>	<b>0.4</b>	<b>1.8</b>	<b>2.2</b>	<b>4.3</b>	<b>6.5</b>				n.m.	-85.9%	-77.5%	-84.9%	-82.9%						
<b>Integration costs/IT costs</b>																											
Integration Cost	1.0	1.4	2.4	0.3	2.7	1.2	1.6	3.9	0.7	1.0	1.7	0.9	2.7				-25.5%	-29.0%	-27.5%	196.1%	-0.9%						
ERP/HR systems	7.1	8.6	15.6	9.8	25.5	-5.7	4.1	19.8	10.3	10.9	21.2	9.2	30.4				45.8%	26.9%	35.5%	-6.1%	19.5%						
<b>Total</b>	<b>8.1</b>	<b>9.9</b>	<b>18.0</b>	<b>10.1</b>	<b>28.1</b>	<b>-4.4</b>	<b>5.7</b>	<b>23.7</b>	<b>11.1</b>	<b>11.8</b>	<b>22.9</b>	<b>10.1</b>	<b>33.1</b>				37.0%	19.2%	27.2%	0.3%	17.5%						
<b>Gain (-)/ losses (+) on the divestment of businesses</b>																											
Costs related to former business activities	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0				n.m.	n.m.	n.m.	n.m.	n.m.						
<b>Total</b>	<b>0.0</b>	<b>0.0</b>	<b>0.0</b>	<b>0.0</b>	<b>0.0</b>	<b>0.0</b>	<b>0.0</b>	<b>0.0</b>	<b>0.0</b>	<b>0.0</b>	<b>0.0</b>	<b>0.0</b>	<b>0.0</b>				n.m.	n.m.	n.m.	n.m.	n.m.						
<b>Other one-time costs</b>																											
Others	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0				n.m.	n.m.	n.m.	n.m.	n.m.						
<b>Total</b>	<b>0.0</b>	<b>0.0</b>	<b>0.0</b>	<b>0.0</b>	<b>0.0</b>	<b>0.0</b>	<b>0.0</b>	<b>0.0</b>	<b>0.0</b>	<b>0.0</b>	<b>0.0</b>	<b>0.0</b>	<b>0.0</b>				n.m.	n.m.	n.m.	n.m.	n.m.						
<b>Total adjustments</b>	<b>5.5</b>	<b>30.4</b>	<b>35.9</b>	<b>40.5</b>	<b>76.5</b>	<b>5.3</b>	<b>45.8</b>	<b>81.8</b>	<b>16.5</b>	<b>13.4</b>	<b>29.9</b>	<b>14.4</b>	<b>44.4</b>				199.6%	-55.9%	-16.7%	-64.4%	-42.0%						
<b>EBITDA pre</b>	<b>927.1</b>	<b>1,005.7</b>	<b>1,932.8</b>	<b>976.4</b>	<b>2,909.2</b>	<b>850.3</b>	<b>1,826.8</b>	<b>3,759.6</b>	<b>900.6</b>	<b>711.9</b>	<b>1,612.5</b>	<b>615.1</b>	<b>2,227.6</b>				-2.9%	-29.2%	-16.6%	-37.0%	-23.4%						

Due to rounding the sum of individual values may not add up to totals presented.

\* Regular depreciation and amortization = Depreciation and amortization - Amortization of purchased intangible assets - Impairments.

\*\* Only reflects impairments classified as adjustments.

**Income Statement Merck KGaA, Darmstadt, Germany**
**Healthcare**

€ million	2022								2023						Change YoY									
	Q1	Q2	H1	Q3	9M	Q4	H2	FY	Q1	Q2	H1	Q3	9M	Q4	H2	FY	Q1	Q2	H1	Q3	9M	Q4	H2	FY
<b>Net sales</b>	<b>1,795.0</b>	<b>1,924.2</b>	<b>3,719.1</b>	<b>2,089.3</b>	<b>5,808.5</b>	<b>2,030.3</b>	<b>4,119.6</b>	<b>7,838.7</b>	<b>1,905.5</b>	<b>2,049.5</b>	<b>3,955.0</b>	<b>2,066.3</b>	<b>6,021.3</b>				6.2%	6.5%	6.3%	-1.1%	3.7%			
Cost of sales	-460.7	-483.5	-944.3	-481.3	-1,425.5	-499.4	-980.7	-1,925.0	-446.6	-485.9	-932.6	-540.0	-1,472.6				-3.1%	0.5%	-1.2%	-1.2%	3.3%			
thereof amortization of intangible assets	-1.2	-1.2	-2.4	-1.2	-3.5	-1.3	-2.5	-4.9	-1.2	-1.2	-2.3	-1.2	-3.5				-0.9%	-1.3%	-1.1%	-2.2%	-1.5%			
Gross profit	1,334.2	1,440.7	2,774.9	1,608.1	4,382.9	1,530.8	3,138.9	5,913.8	1,458.9	1,563.6	3,022.4	1,526.2	4,548.7				9.3%	8.5%	8.9%	-5.1%	3.8%			
<i>in % of net sales</i>	74.3%	74.9%	74.6%	77.0%	75.5%	75.4%	76.2%	75.4%	76.6%	76.3%	76.4%	73.9%	75.5%											
SG&A	-482.9	-601.3	-1,084.2	-570.7	-1,654.9	-670.0	-1,240.7	-2,324.9	-543.9	-546.4	-1,090.2	-481.7	-1,571.9				12.6%	-9.1%	0.6%	-15.6%	-5.0%			
<i>in % of net sales</i>	26.9%	31.2%	29.2%	27.3%	28.5%	33.0%	30.1%	29.7%	28.5%	26.7%	27.6%	23.3%	26.1%											
Marketing and selling expenses	-375.6	-416.9	-792.5	-412.9	-1,205.4	-438.9	-851.8	-1,644.3	-380.6	-422.4	-803.0	-405.5	-1,208.5				1.3%	1.3%	1.3%	-1.8%	0.3%			
thereof amortization of intangible assets (M&S)	-0.2	-0.2	-0.4	-0.1	-0.5	1.1	1.0	0.6	-0.3	-0.4	-0.7	-0.5	-1.2				29.8%	147.1%	76.3%	422.7%	137.9%			
Administration expenses	-71.2	-81.1	-152.3	-83.5	-235.8	-77.5	-161.0	-313.3	-75.5	-79.3	-154.8	-78.8	-233.6				6.0%	-2.2%	1.6%	-5.7%	-0.9%			
Impairment losses and reversals (IFRS 9)	-3.7	-0.5	-4.2	4.5	0.3	2.2	6.7	2.5	-1.0	-8.4	-9.4	-28.4	-37.8				-73.5%	>1.000%	124.4%	n.m.	n.m.			
Other operating expenses/income	-32.4	-102.9	-135.3	-78.7	-214.0	-155.8	-234.6	-369.8	-86.8	-36.2	-123.0	30.9	-92.0				167.7%	-64.8%	-9.1%	n.m.	-57.0%			
Impairments**	-0.8	-89.9	-90.8	-0.5	-91.2	-95.7	-96.2	-187.0	0.6	0.0	0.6	0.0	0.6				n.m.	n.m.	n.m.	-100.0%	n.m.			
Research and development costs	-397.4	-400.7	-798.1	-431.4	-1,229.5	-464.8	-896.2	-1,694.3	-395.3	-401.5	-796.7	-391.3	-1,188.0				-0.5%	0.2%	-0.2%	-9.3%	-3.4%			
<i>in % of net sales</i>	22.1%	20.8%	21.5%	20.6%	21.2%	22.9%	21.8%	21.6%	20.7%	19.6%	20.1%	18.9%	19.7%											
thereof amortization of intangible assets (R&D)	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-0.1	-0.1	-0.1	-0.1	-0.2				n.m.	n.m.	n.m.	n.m.	n.m.			
<b>EBIT</b>	<b>453.9</b>	<b>438.7</b>	<b>892.6</b>	<b>606.0</b>	<b>1,498.5</b>	<b>396.1</b>	<b>1,002.0</b>	<b>1,894.6</b>	<b>519.7</b>	<b>615.8</b>	<b>1,135.5</b>	<b>653.2</b>	<b>1,788.7</b>				14.5%	40.4%	27.2%	7.8%	19.4%			
<i>in % of net sales</i>	25.3%	22.8%	24.0%	29.0%	25.8%	19.5%	24.3%	24.2%	27.3%	30.0%	28.7%	31.6%	29.7%											
Depreciation and amortization	71.7	164.0	235.7	76.7	312.4	177.9	254.6	490.2	72.9	76.2	149.1	70.2	219.4				1.7%	-53.5%	-36.7%	-8.4%	-29.8%			
<b>EBITDA</b>	<b>525.6</b>	<b>602.7</b>	<b>1,128.3</b>	<b>682.6</b>	<b>1,810.9</b>	<b>573.9</b>	<b>1,256.6</b>	<b>2,384.8</b>	<b>592.6</b>	<b>692.0</b>	<b>1,284.6</b>	<b>723.4</b>	<b>2,008.1</b>				12.8%	14.8%	13.9%	6.0%	10.9%			
<i>in % of net sales</i>	29.3%	31.3%	30.3%	32.7%	31.2%	28.3%	30.5%	30.4%	31.1%	33.8%	32.5%	35.0%	33.3%											
<b>EBITDA pre</b>	<b>529.1</b>	<b>603.6</b>	<b>1,132.7</b>	<b>710.9</b>	<b>1,843.5</b>	<b>633.1</b>	<b>1,343.9</b>	<b>2,476.6</b>	<b>589.6</b>	<b>703.6</b>	<b>1,293.2</b>	<b>685.4</b>	<b>1,978.5</b>				11.4%	16.6%	14.2%	-3.6%	7.3%			
<i>in % of net sales</i>	29.5%	31.4%	30.5%	34.0%	31.7%	31.2%	32.6%	31.6%	30.9%	34.3%	32.7%	33.2%	32.9%											
<b>Reconciliation to EBITDA pre</b>																								
EBITDA	525.6	602.7	1,128.3	682.6	1,810.9	573.9	1,256.6	2,384.8	592.6	692.0	1,284.6	723.4	2,008.1				12.8%	14.8%	13.9%	6.0%	10.9%			
<b>Adjustments</b>																								
thereof: Cost of Sales	0.4	1.1	1.5	0.8	2.3	1.3	2.0	3.6	0.2	-1.7	-1.5	0.3	-1.3				-52.0%	n.m.	n.m.	-65.2%	n.m.			
thereof: Marketing and selling expenses	0.4	1.4	1.8	1.2	3.1	9.8	11.0	12.9	0.3	4.6	4.9	5.7	10.6				-24.4%	220.0%	165.6%	365.0%	244.8%			
thereof: Administration expenses	2.0	2.9	4.9	4.1	9.0	8.5	12.6	17.5	4.0	3.5	7.4	5.1	12.5				103.6%	18.8%	52.8%	23.4%	39.4%			
thereof: Other operating expenses/income	0.0	-10.1	-10.1	0.0	-10.1	-4.8	-4.8	-14.8	0.3	0.3	0.6	-49.3	-48.7				n.m.	n.m.	n.m.	>1.000%	382.8%			
thereof: Research and development	0.7	5.5	6.3	22.1	28.4	44.3	66.4	72.7	-7.8	5.0	-2.8	0.2	-2.6				n.m.	-9.3%	n.m.	-99.1%	n.m.			
<b>Total</b>	<b>3.5</b>	<b>0.9</b>	<b>4.4</b>	<b>28.2</b>	<b>32.6</b>	<b>59.1</b>	<b>87.3</b>	<b>91.8</b>	<b>-3.0</b>	<b>11.6</b>	<b>8.6</b>	<b>-38.1</b>	<b>-29.5</b>				n.m.	>1.000%	93.5%	n.m.	n.m.			
<b>EBITDA pre</b>	<b>529.1</b>	<b>603.6</b>	<b>1,132.7</b>	<b>710.9</b>	<b>1,843.5</b>	<b>633.1</b>	<b>1,343.9</b>	<b>2,476.6</b>	<b>589.6</b>	<b>703.6</b>	<b>1,293.2</b>	<b>685.4</b>	<b>1,978.5</b>				11.4%	16.6%	14.2%	-3.6%	7.3%			

Due to rounding the sum of individual values may not add up to totals presented.

**Detailed reconciliation - Healthcare**

€ million	2022								2023						Change YoY												
	Q1	Q2	H1	Q3	9M	Q4	H2	FY	Q1	Q2	H1	Q3	9M	Q4	H2	FY	Q1	Q2	H1	Q3	9M	Q4	H2	FY			
<b>EBIT</b>	<b>453.9</b>	<b>438.7</b>	<b>892.6</b>	<b>606.0</b>	<b>1,498.5</b>	<b>396.1</b>	<b>1,002.0</b>	<b>1,894.6</b>	<b>519.7</b>	<b>615.8</b>	<b>1,135.5</b>	<b>653.2</b>	<b>1,788.7</b>				14.5%	40.4%	27.2%	7.8%	19.4%						
Regular depreciation and amortization*	69.5	72.7	142.2	74.9	217.1	81.7	156.6	298.7	71.9	70.4	142.3	68.5	210.9				3.5%	-3.1%	0.1%	-8.5%	-2.9%						
Impairments not adjusted	0.0	0.0	0.0	0.0	0.0	0.2	0.2	0.2	0.0	4.2	4.2	0.0	4.2				n.m.	n.m.	n.m.	-100.0%	>1.000%						
Amortization of purchased intangible assets	1.4	1.3	2.8	1.3	4.0	0.3	1.5	4.3	1.5	1.6	3.2	1.7	4.8				8.5%	20.9%	14.5%	31.7%	19.9%						
Impairments (net)**	0.8	89.9	90.8	0.5	91.2	95.7	96.2	187.0	-0.6	0.0	-0.6	0.0	-0.6				n.m.	n.m.	n.m.	-100.0%	n.m.						
<b>Total depreciation and amortization</b>	<b>71.7</b>	<b>164.0</b>	<b>235.7</b>	<b>76.7</b>	<b>312.4</b>	<b>177.9</b>	<b>254.6</b>	<b>490.2</b>	<b>72.9</b>	<b>76.2</b>	<b>149.1</b>	<b>70.2</b>	<b>219.4</b>				1.7%	-53.5%	-36.7%	-8.4%	-29.8%						
<b>EBITDA</b>	<b>525.6</b>	<b>602.7</b>	<b>1,128.3</b>	<b>682.6</b>	<b>1,810.9</b>	<b>573.9</b>	<b>1,256.6</b>	<b>2,384.8</b>	<b>592.6</b>	<b>692.0</b>	<b>1,284.6</b>	<b>723.4</b>	<b>2,008.1</b>				12.8%	14.8%	13.9%	6.0%	10.9%						
<b>Adjustments</b>																											
<b>Acquisition costs</b>	<b>0.0</b>	<b>0.0</b>	<b>0.0</b>	<b>0.0</b>	<b>0.0</b>	<b>0.0</b>	<b>0.0</b>	<b>0.0</b>	<b>0.0</b>	<b>0.0</b>	<b>0.0</b>	<b>0.0</b>	<b>0.0</b>				n.m.	n.m.	n.m.	n.m.	n.m.						
<b>Restructuring costs</b>																											
Restructuring costs	1.9	8.3	10.2	24.5	34.7	56.3	80.7	91.0	-7.3	12.0	4.7	2.6	7.3				n.m.	44.8%	-54.0%	-89.3%	-78.9%						
<b>Total</b>	<b>1.9</b>	<b>8.3</b>	<b>10.2</b>	<b>24.5</b>	<b>34.7</b>	<b>56.3</b>	<b>80.7</b>	<b>91.0</b>	<b>-7.3</b>	<b>12.0</b>	<b>4.7</b>	<b>2.6</b>	<b>7.3</b>				n.m.	44.8%	-54.0%	-89.3%	-78.9%						
<b>Integration costs/IT costs</b>																											
Integration Cost	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0				n.m.	n.m.	n.m.	n.m.	n.m.						
ERP/HR systems	1.6	2.7	4.3	3.7	8.1	7.6	11.3	15.6	4.0	3.5	7.4	5.1	12.5				149.9%	27.4%	72.4%	35.4%	55.2%						
<b>Total</b>	<b>1.6</b>	<b>2.7</b>	<b>4.3</b>	<b>3.7</b>	<b>8.1</b>	<b>7.6</b>	<b>11.3</b>	<b>15.6</b>	<b>4.0</b>	<b>3.5</b>	<b>7.4</b>	<b>5.1</b>	<b>12.5</b>				149.9%	27.4%	72.4%	35.4%	55.2%						
<b>Gain (-)/ losses (+) on the divestment of businesses</b>																											
Sale of Kuvan and Biosimilars	0.0	-9.8	-9.8	0.0	-9.8	-4.7	-4.7	-14.4	0.0	-7.6	-7.6	-50.5	-58.1				>1.000%	-22.4%	-22.2%	n.m.	494.6%						
Sale of Consumer Health	0.0	-0.3	-0.4	0.0	-0.3	-0.4	-0.4	-0.7	0.0	4.3	4.3	4.7	9.0				n.m.	n.m.	n.m.	>1.000%	n.m.						
Sale of Allergopharma	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0				n.m.	n.m.	n.m.	n.m.	n.m.						
Others	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0				n.m.	n.m.	n.m.	n.m.	n.m.						
<b>Total</b>	<b>0.0</b>	<b>-10.1</b>	<b>-10.1</b>	<b>0.0</b>	<b>-10.1</b>	<b>-4.7</b>	<b>-4.7</b>	<b>-14.8</b>	<b>0.3</b>	<b>-3.9</b>	<b>-3.6</b>	<b>-45.8</b>	<b>-49.4</b>				n.m.	-61.5%	-64.5%	n.m.	387.9%						
<b>Other one-time costs</b>																											
Others	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0				-100.0%	n.m.	-100.0%	n.m.	-100.0%						
<b>Total</b>	<b>0.0</b>	<b>0.0</b>	<b>0.0</b>	<b>0.0</b>	<b>0.0</b>	<b>0.0</b>	<b>0.0</b>	<b>0.0</b>	<b>0.0</b>	<b>0.0</b>	<b>0.0</b>	<b>0.0</b>	<b>0.0</b>				-100.0%	n.m.	-100.0%	n.m.	-100.0%						
<b>Total adjustments</b>	<b>3.5</b>	<b>0.9</b>	<b>4.4</b>	<b>28.2</b>	<b>32.6</b>	<b>59.1</b>	<b>87.3</b>	<b>91.8</b>	<b>-3.0</b>	<b>11.6</b>	<b>8.6</b>	<b>-38.1</b>	<b>-29.5</b>				n.m.	>1.000%	93.5%	n.m.	n.m.						
<b>EBITDA pre</b>	<b>529.1</b>	<b>603.6</b>	<b>1,132.7</b>	<b>710.9</b>	<b>1,843.5</b>	<b>633.1</b>	<b>1,343.9</b>	<b>2,476.6</b>	<b>589.6</b>	<b>703.6</b>	<b>1,293.2</b>	<b>685.4</b>	<b>1,978.5</b>				11.4%	16.6%	14.2%	-3.6%	7.3%						

Due to rounding the sum of individual values may not add up to totals presented.

\* Regular depreciation and amortization = Depreciation and amortization - Amortization of purchased intangible assets - Impairments.

\*\* Only reflects impairments classified as adjustments.



**Detailed reconciliation - Electronics**

€ million	2022								2023								Change YoY							
	Q1	Q2	H1	Q3	9M	Q4	H2	FY	Q1	Q2	H1	Q3	9M	Q4	H2	FY	Q1	Q2	H1	Q3	9M	Q4	H2	FY
<b>EBIT</b>	<b>145.2</b>	<b>148.5</b>	<b>293.7</b>	<b>143.9</b>	<b>437.5</b>	<b>134.9</b>	<b>278.8</b>	<b>572.5</b>	<b>85.7</b>	<b>110.1</b>	<b>195.8</b>	<b>52.3</b>	<b>248.1</b>				-41.0%	-25.8%	-33.3%	-63.7%	-43.3%			
Regular depreciation and amortization*	47.9	47.3	95.2	50.7	145.9	51.0	101.8	197.0	48.2	49.1	97.3	49.7	147.0				0.6%	3.9%	2.2%	-2.0%	0.8%			
Impairments not adjusted	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0				n.m.	n.m.	n.m.	n.m.	n.m.			
Amortization of purchased intangible assets	85.4	86.3	171.7	89.0	260.7	87.3	176.3	348.0	84.1	80.6	164.7	80.1	244.8				-1.6%	-6.5%	-4.1%	-10.1%	-6.1%			
Impairments (net)**	0.3	0.0	0.3	10.4	10.7	9.4	19.8	20.1	10.3	5.0	15.3	3.7	18.9				>1.000%	>1.000%	>1.000%	-64.6%	77.1%			
<b>Total depreciation and amortization</b>	<b>133.6</b>	<b>133.6</b>	<b>267.1</b>	<b>150.2</b>	<b>417.3</b>	<b>147.7</b>	<b>297.9</b>	<b>565.1</b>	<b>142.6</b>	<b>134.7</b>	<b>277.3</b>	<b>133.5</b>	<b>410.8</b>				6.7%	0.9%	3.8%	-11.1%	-1.6%			
<b>EBITDA</b>	<b>278.8</b>	<b>282.0</b>	<b>560.8</b>	<b>294.1</b>	<b>854.9</b>	<b>282.7</b>	<b>576.8</b>	<b>1,137.6</b>	<b>228.2</b>	<b>244.8</b>	<b>473.1</b>	<b>185.8</b>	<b>658.8</b>				-18.1%	-13.2%	-15.6%	-36.8%	-22.9%			
<b>Adjustments</b>																								
<b>Acquisition costs</b>	<b>1.0</b>	<b>1.1</b>	<b>2.1</b>	<b>5.1</b>	<b>7.3</b>	<b>4.2</b>	<b>9.3</b>	<b>11.4</b>	<b>4.2</b>	<b>5.1</b>	<b>9.2</b>	<b>3.7</b>	<b>12.9</b>				302.6%	354.8%	329.6%	-28.5%	77.5%			
<b>Restructuring costs</b>																								
Restructuring costs	4.7	8.5	13.1	3.4	16.6	14.0	17.4	30.6	2.2	6.9	9.1	9.9	18.9				-53.7%	-18.4%	-30.9%	189.6%	14.5%			
<b>Total</b>	<b>4.7</b>	<b>8.5</b>	<b>13.1</b>	<b>3.4</b>	<b>16.6</b>	<b>14.0</b>	<b>17.4</b>	<b>30.6</b>	<b>2.2</b>	<b>6.9</b>	<b>9.1</b>	<b>9.9</b>	<b>18.9</b>				-53.7%	-18.4%	-30.9%	189.6%	14.5%			
<b>Integration costs/IT costs</b>																								
Integration Cost	3.9	0.3	4.3	-2.4	1.8	2.9	0.5	4.8	1.1	1.0	2.1	1.2	3.3				-71.4%	224.3%	-49.5%	n.m.	82.8%			
ERP/HR systems	0.9	1.1	2.1	1.4	3.5	4.4	5.8	7.9	1.7	3.9	5.6	7.4	13.0				79.2%	238.8%	167.4%	419.0%	270.1%			
<b>Total</b>	<b>4.9</b>	<b>1.5</b>	<b>6.3</b>	<b>-1.0</b>	<b>5.3</b>	<b>7.3</b>	<b>6.3</b>	<b>12.6</b>	<b>2.8</b>	<b>4.9</b>	<b>7.7</b>	<b>8.6</b>	<b>16.3</b>				-42.6%	235.7%	21.6%	n.m.	206.2%			
<b>Gain (-)/ losses (+) on the divestment of businesses</b>																								
Costs related to former business activities	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0				n.m.	n.m.	n.m.	n.m.	n.m.			
<b>Total</b>	<b>0.0</b>	<b>0.0</b>	<b>0.0</b>	<b>0.0</b>	<b>0.0</b>	<b>0.0</b>	<b>0.0</b>	<b>0.0</b>	<b>0.0</b>	<b>0.0</b>	<b>0.0</b>	<b>0.0</b>	<b>0.0</b>				n.m.	n.m.	n.m.	n.m.	n.m.			
<b>Other one-time costs</b>																								
Others	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0				n.m.	n.m.	n.m.	n.m.	n.m.			
<b>Total</b>	<b>0.0</b>	<b>0.0</b>	<b>0.0</b>	<b>0.0</b>	<b>0.0</b>	<b>0.0</b>	<b>0.0</b>	<b>0.0</b>	<b>0.0</b>	<b>0.0</b>	<b>0.0</b>	<b>0.0</b>	<b>0.0</b>				n.m.	n.m.	n.m.	n.m.	n.m.			
<b>Total adjustments</b>	<b>10.6</b>	<b>11.1</b>	<b>21.6</b>	<b>7.5</b>	<b>29.1</b>	<b>25.5</b>	<b>33.0</b>	<b>54.6</b>	<b>9.1</b>	<b>16.9</b>	<b>26.0</b>	<b>22.1</b>	<b>48.1</b>				-13.7%	52.8%	20.3%	194.6%	65.2%			
<b>EBITDA pre</b>	<b>289.3</b>	<b>293.1</b>	<b>582.4</b>	<b>301.6</b>	<b>884.0</b>	<b>308.2</b>	<b>609.8</b>	<b>1,192.2</b>	<b>237.3</b>	<b>261.7</b>	<b>499.1</b>	<b>207.9</b>	<b>707.0</b>				-18.0%	-10.7%	-14.3%	-31.1%	-20.0%			

Due to rounding the sum of individual values may not add up to totals presented.

\* Regular depreciation and amortization = Depreciation and amortization - Amortization of purchased intangible assets - Impairments.

\*\* Only reflects impairments classified as adjustments.

**Income Statement Merck KGaA, Darmstadt, Germany  
Corporate and Other**

€ million	2022								2023								Change YoY										
	Q1	Q2	H1	Q3	9M	Q4	H2	FY	Q1	Q2	H1	Q3	9M	Q4	H2	FY	Q1	Q2	H1	Q3	9M	Q4	H2	FY			
<b>Net sales</b>	<b>0.0</b>	<b>0.0</b>	<b>0.0</b>	<b>0.0</b>	<b>0.0</b>	<b>0.0</b>	<b>0.0</b>	<b>0.0</b>	<b>0.0</b>	<b>0.0</b>	<b>0.0</b>	<b>0.0</b>	<b>0.0</b>	<b>0.0</b>			n.m.	n.m.	n.m.	n.m.	n.m.						
Cost of sales	-1.2	-2.0	-3.2	-4.7	-7.9	-0.8	-5.5	-8.7	-0.9	-2.6	-3.5	1.6	-1.9				-24.8%	31.8%	10.2%	n.m.	-76.4%						
thereof amortization of intangible assets	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0				n.m.	n.m.	n.m.	n.m.	n.m.						
Gross profit	-1.2	-2.0	-3.2	-4.7	-7.9	-0.8	-5.5	-8.7	-0.9	-2.6	-3.5	1.6	-1.9				-24.8%	31.8%	10.2%	n.m.	-76.4%						
SG&A	-123.0	-146.0	-269.0	-204.0	-473.1	-200.4	-404.5	-673.5	-217.8	-183.9	-401.7	-95.4	-497.1				77.0%	25.9%	49.3%	-53.3%	5.1%						
Marketing and selling expenses	-4.0	-4.7	-8.7	-4.1	-12.8	5.9	1.8	-7.0	-2.8	-3.1	-5.9	0.5	-5.4				-28.5%	-35.2%	-32.2%	n.m.	-58.0%						
thereof amortization of intangible assets (M&S)	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0				4.6%	-2.2%	1.1%	-7.5%	-1.9%						
Administration expenses	-96.3	-113.8	-210.1	-99.3	-309.3	-156.3	-255.6	-465.6	-144.4	-127.9	-272.3	-90.5	-362.8				50.0%	12.4%	29.6%	-8.9%	17.3%						
Impairment losses and reversals (IFRS 9)	0.2	-0.3	-0.1	0.3	0.2	0.7	1.0	0.9	0.0	0.0	0.0	0.0	0.0				-87.2%	n.m.	n.m.	-97.7%	-80.4%						
Other operating expenses/income	-23.0	-27.2	-50.2	-100.9	-151.1	-50.7	-151.6	-201.8	-70.6	-52.9	-123.5	-5.4	-128.9				207.0%	94.7%	146.2%	-94.6%	-14.7%						
Impairments**	-0.3	0.0	-0.3	0.0	-0.3	-0.1	-0.1	-0.4	0.0	0.0	0.0	-0.1	-0.1				-100.0%	-100.0%	-100.0%	>1.000%	-61.5%						
Research and development costs	-24.7	-27.5	-52.2	-26.2	-78.4	-40.4	-66.6	-118.8	-24.1	-25.3	-49.4	-24.7	-74.0				-2.5%	-8.1%	-5.4%	-5.7%	-5.5%						
thereof amortization of intangible assets (R&D)	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0				n.m.	n.m.	n.m.	n.m.	n.m.						
<b>EBIT</b>	<b>-148.9</b>	<b>-175.5</b>	<b>-324.4</b>	<b>-234.9</b>	<b>-559.3</b>	<b>-241.6</b>	<b>-476.5</b>	<b>-800.9</b>	<b>-242.8</b>	<b>-211.7</b>	<b>-454.5</b>	<b>-118.4</b>	<b>-572.9</b>				63.0%	20.7%	40.1%	-49.6%	2.4%						
Depreciation and amortization	25.9	24.9	50.8	26.2	77.0	28.0	54.2	105.1	28.4	28.2	56.6	26.9	83.5				9.5%	13.2%	11.4%	2.8%	8.5%						
<b>EBITDA</b>	<b>-123.0</b>	<b>-150.6</b>	<b>-273.6</b>	<b>-208.7</b>	<b>-482.3</b>	<b>-213.6</b>	<b>-422.3</b>	<b>-695.9</b>	<b>-214.4</b>	<b>-183.5</b>	<b>-397.9</b>	<b>-91.5</b>	<b>-489.4</b>				74.3%	21.9%	45.5%	-56.2%	1.5%						
<b>EBITDA pre</b>	<b>-116.8</b>	<b>-120.3</b>	<b>-237.1</b>	<b>-178.4</b>	<b>-415.5</b>	<b>-163.7</b>	<b>-342.0</b>	<b>-579.2</b>	<b>-140.5</b>	<b>-123.9</b>	<b>-264.5</b>	<b>-62.7</b>	<b>-327.2</b>				20.3%	3.0%	11.5%	-64.8%	-21.3%						
<b>Reconciliation to EBITDA pre</b>																											
EBITDA	-123.0	-150.6	-273.6	-208.7	-482.3	-213.6	-422.3	-695.9	-214.4	-183.5	-397.9	-91.5	-489.4				74.3%	21.9%	45.5%	-56.2%	1.5%						
<b>Adjustments</b>																											
thereof: Cost of Sales	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.4	0.6	0.0	0.7				>1.000%	>1.000%	>1.000%	>1.000%	>1.000%						
thereof: Marketing and selling expenses	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0				-100.0%	n.m.	-100.0%	n.m.	-100.0%						
thereof: Administration expenses	10.2	15.8	26.0	15.9	41.9	25.2	41.1	67.1	54.6	22.8	77.5	12.2	89.6				438.1%	44.2%	198.1%	-23.3%	114.2%						
thereof: Other operating expenses/income	-3.9	14.4	10.4	14.5	24.9	24.7	39.2	49.6	19.0	35.0	54.0	16.6	70.6				n.m.	143.3%	417.5%	14.3%	183.2%						
thereof: Research and development	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.3	1.3	0.0	1.3				n.m.	n.m.	n.m.	n.m.	n.m.						
<b>Total</b>	<b>6.2</b>	<b>30.2</b>	<b>36.4</b>	<b>30.3</b>	<b>66.8</b>	<b>49.9</b>	<b>80.2</b>	<b>116.7</b>	<b>73.9</b>	<b>59.6</b>	<b>133.5</b>	<b>28.8</b>	<b>162.2</b>				>1.000%	97.1%	266.3%	-5.2%	142.9%						
<b>EBITDA pre</b>	<b>-116.8</b>	<b>-120.3</b>	<b>-237.1</b>	<b>-178.4</b>	<b>-415.5</b>	<b>-163.7</b>	<b>-342.0</b>	<b>-579.2</b>	<b>-140.5</b>	<b>-123.9</b>	<b>-264.5</b>	<b>-62.7</b>	<b>-327.2</b>				20.3%	3.0%	11.5%	-64.8%	-21.3%						

Due to rounding the sum of individual values may not add up to totals presented.

\*\* Only reflects impairments classified as adjustments.

**Detailed reconciliation - Corporate and Others**

€ million	2022								2023					Change YoY										
	Q1	Q2	H1	Q3	9M	Q4	H2	FY	Q1	Q2	H1	Q3	9M	Q4	H2	FY	Q1	Q2	H1	Q3	9M	Q4	H2	FY
<b>EBIT</b>	-148.9	-175.5	-324.4	-234.9	-559.3	-241.6	-476.5	-800.9	-242.8	-211.7	-454.5	-118.4	-572.9				63.0%	20.7%	40.1%	-49.6%	2.4%			
Regular depreciation and amortization*	25.7	24.9	50.6	26.2	76.7	28.0	54.1	104.7	28.4	28.2	56.6	26.8	83.4				10.7%	13.3%	11.9%	2.4%	8.7%			
Impairments not adjusted	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0											
Amortization of purchased intangible assets	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0				4.6%	-2.2%	1.1%	-7.5%	-1.9%			
Impairments (net)**	0.3	0.0	0.3	0.0	0.3	0.1	0.1	0.4	0.0	0.0	0.0	0.1	0.1				-100.0%	-100.0%	-100.0%	>1.000%	-61.5%			
<b>Total depreciation and amortization</b>	<b>25.9</b>	<b>24.9</b>	<b>50.8</b>	<b>26.2</b>	<b>77.0</b>	<b>28.0</b>	<b>54.2</b>	<b>105.1</b>	<b>28.4</b>	<b>28.2</b>	<b>56.6</b>	<b>26.9</b>	<b>83.5</b>				9.5%	13.2%	11.4%	2.8%	8.5%			
<b>EBITDA</b>	<b>-123.0</b>	<b>-150.6</b>	<b>-273.6</b>	<b>-208.7</b>	<b>-482.3</b>	<b>-213.6</b>	<b>-422.3</b>	<b>-695.9</b>	<b>-214.4</b>	<b>-183.5</b>	<b>-397.9</b>	<b>-91.5</b>	<b>-489.4</b>				74.3%	21.9%	45.5%	-56.2%	1.5%			
<b>Adjustments</b>																								
<b>Acquisition costs</b>	<b>0.0</b>	<b>0.0</b>	<b>0.0</b>	<b>0.0</b>	<b>0.0</b>	<b>0.0</b>	<b>0.0</b>	<b>0.0</b>	<b>0.0</b>	<b>0.0</b>	<b>0.0</b>	<b>0.0</b>	<b>0.0</b>				n.m.	n.m.	n.m.	n.m.	n.m.			
<b>Restructuring costs</b>																								
Restructuring costs	4.8	7.9	12.8	7.0	19.8	16.5	23.5	36.3	49.0	18.5	67.6	7.9	75.4				>1.000%	133.6%	429.4%	12.2%	281.6%			
<b>Total</b>	<b>4.8</b>	<b>7.9</b>	<b>12.8</b>	<b>7.0</b>	<b>19.8</b>	<b>16.5</b>	<b>23.5</b>	<b>36.3</b>	<b>49.0</b>	<b>18.5</b>	<b>67.6</b>	<b>7.9</b>	<b>75.4</b>				>1.000%	133.6%	429.4%	12.2%	281.6%			
<b>IT project costs</b>																								
Integration Cost	0.0	0.5	0.5	0.0	0.5	0.0	0.1	0.6	0.0	0.1	0.1	0.1	0.2											
ERP/HR systems	5.4	9.6	15.0	9.8	24.8	10.2	20.0	35.0	5.6	6.8	12.4	4.9	17.3				3.6%	-29.0%	-17.3%	-49.8%	-30.2%			
<b>Total</b>	<b>5.4</b>	<b>10.1</b>	<b>15.5</b>	<b>9.9</b>	<b>25.4</b>	<b>10.2</b>	<b>20.1</b>	<b>35.6</b>	<b>5.6</b>	<b>6.9</b>	<b>12.5</b>	<b>5.0</b>	<b>17.5</b>				4.2%	-31.8%	-19.2%	-49.4%	-31.0%			
<b>Gain (-)/ losses (+) on the divestment of businesses</b>																								
Costs related to former business activities	-10.3	-11.5	-21.8	-4.1	-25.9	3.2	-0.9	-22.7	0.0	21.0	21.0	-3.0	18.0				-100.0%	n.m.	n.m.	-26.6%	n.m.			
<b>Total</b>	<b>-10.3</b>	<b>-11.5</b>	<b>-21.8</b>	<b>-4.1</b>	<b>-25.9</b>	<b>3.2</b>	<b>-0.9</b>	<b>-22.7</b>	<b>0.0</b>	<b>21.0</b>	<b>21.0</b>	<b>-3.0</b>	<b>18.0</b>				-100.0%	n.m.	n.m.	-26.6%	n.m.			
<b>Other one-time costs</b>																								
Others	6.2	23.8	30.0	17.5	47.5	20.0	37.5	67.5	19.2	13.2	32.4	18.9	51.3				208.4%	-44.5%	8.0%	7.8%	7.9%			
<b>Total</b>	<b>6.2</b>	<b>23.8</b>	<b>30.0</b>	<b>17.5</b>	<b>47.5</b>	<b>20.0</b>	<b>37.5</b>	<b>67.5</b>	<b>19.2</b>	<b>13.2</b>	<b>32.4</b>	<b>18.9</b>	<b>51.3</b>				208.4%	-44.5%	8.0%	7.8%	7.9%			
<b>Total adjustments</b>	<b>6.2</b>	<b>30.2</b>	<b>36.4</b>	<b>30.3</b>	<b>66.8</b>	<b>49.9</b>	<b>80.2</b>	<b>116.7</b>	<b>73.9</b>	<b>59.6</b>	<b>133.5</b>	<b>28.8</b>	<b>162.2</b>				>1.000%	97.1%	266.3%	-5.2%	142.9%			
<b>EBITDA pre</b>	<b>-116.8</b>	<b>-120.3</b>	<b>-237.1</b>	<b>-178.4</b>	<b>-415.5</b>	<b>-163.7</b>	<b>-342.0</b>	<b>-579.2</b>	<b>-140.5</b>	<b>-123.9</b>	<b>-264.5</b>	<b>-62.7</b>	<b>-327.2</b>				20.3%	3.0%	11.5%	-64.8%	-21.3%			

Due to rounding the sum of individual values may not add up to totals presented.

\* Regular depreciation and amortization = Depreciation and amortization - Amortization of purchased intangible assets - Impairments.

\*\* Only reflects impairments classified as adjustments.

Income Statement Merck KGaA, Darmstadt, Germany

Group € million	2022								2023							Change YoY								
	Q1	Q2	H1	Q3	9M	Q4	H2	FY	Q1	Q2	H1	Q3	9M	Q4	H2	FY	Q1	Q2	H1	Q3	9M	Q4	H2	FY
<b>Financial result</b>	-34.3	-55.1	-89.4	-47.0	-136.4	-50.5	-97.5	-186.9	-22.7	-75.7	-98.4	-46.0	-144.3				-33.9%	37.4%	10.0%	-2.3%	5.8%			
<b>Interest result</b>	-23.0	-48.9	-71.9	-22.3	-94.2	-30.0	-52.4	-124.3	-27.4	-48.7	-76.1	-39.2	-115.3				19.0%	-0.3%	5.9%	75.4%	22.3%			
Interest income	25.0	7.4	32.4	28.6	60.9	8.4	37.0	69.4	20.6	36.7	57.3	25.0	82.2				-17.7%	397.6%	76.9%	-12.6%	35.0%			
Interest expenses	-48.0	-56.2	-104.3	-50.9	-155.2	-38.5	-89.4	-193.7	-48.0	-85.4	-133.4	-64.1	-197.5				-0.1%	51.9%	27.9%	26.0%	27.3%			
<b>Result from financial investments</b>	-3.0	-3.7	-6.8	-2.2	-8.9	6.9	4.8	-2.0	13.4	7.4	20.8	12.7	33.5				n.m.	n.m.	n.m.	n.m.	n.m.			
<b>Currency difference - financing</b>	-2.5	-7.1	-9.6	-6.4	-16.0	-10.4	-16.9	-26.4	-1.4	-4.8	-6.3	5.6	-0.6				-41.3%	-32.1%	-34.5%	n.m.	-96.2%			
<b>Interest quota - pensions and other provis</b>	-5.9	4.7	-1.1	-16.1	-17.2	-16.9	-33.0	-34.1	-7.3	-29.5	-36.8	-25.1	-61.9				24.0%	n.m.	>1.000%	56.0%	260.0%			
<b>Others</b>	0.1	-0.1	0.0	0.0	0.0	0.0	0.0	-0.1	0.0	0.0	0.0	0.0	0.0				n.m.	-100.0%	-100.0%	-100.0%	-100.0%			

Cash Flow Statement Merck KGaA, Darmstadt, Germany

Group	2022								2023								Change YoY								
	Q1	Q2	H1	Q3	9M	Q4	H2	FY	Q1	Q2	H1	Q3	9M	Q4	H2	FY	Q1	Q2	H1	Q3	9M	Q4	H2	FY	
€ million																									
<b>Profit after tax</b>	883.7	870.2	1,754.0	926.0	2,679.9	659.3	1,585.3	3,339.3	799.7	706.1	1,505.8	740.4	2,246.2				-9.5%	-18.9%	-14.1%	-20.0%	-16.2%				
Depreciation/amortization/impairment losses/reversals of impairment losses	429.6	532.3	961.9	469.7	1,431.6	598.5	1,068.2	2,030.1	455.5	482.3	937.8	435.2	1,373.0				6.0%	-9.4%	-2.5%	-7.3%	-4.1%				
of tangible assets	206.7	208.8	415.4	219.3	634.7	252.7	472.0	887.4	216.6	216.7	433.3	224.3	657.6				4.8%	3.8%	4.3%	2.3%	3.6%				
of intangible assets	222.9	323.6	546.5	250.4	796.8	345.8	596.2	1,142.7	238.9	265.6	504.5	210.9	715.4				7.2%	-17.9%	-7.7%	-15.8%	-10.2%				
Changes in working capital	-322.3	-324.9	-647.2	-180.7	-827.9	-88.8	-269.5	-916.7	-223.9	-52.9	-276.8	-35.2	-312.0				-30.5%	-83.7%	-57.2%	-80.5%	-62.3%				
Changes in inventories	-186.4	-200.7	-387.1	-248.6	-635.7	31.5	-217.2	-604.2	-322.5	-106.3	-428.9	91.8	-337.0				73.0%	-47.0%	10.8%	n.m.	-47.0%				
Changes in trade accounts receivable	-343.1	-193.8	-536.9	149.1	-387.8	-25.3	123.8	-413.1	-116.5	14.7	-101.8	51.8	-50.0				-66.0%	n.m.	-81.0%	-65.3%	-87.1%				
Changes in trade accounts payable/ refund liabilities	207.2	69.6	276.8	-81.2	195.6	-95.0	-176.1	100.7	215.1	38.8	253.9	-178.8	75.1				3.8%	-44.3%	-8.3%	120.2%	-61.6%				
Changes in provisions <sup>1</sup>	106.6	-92.5	14.1	111.2	125.3	153.7	264.9	279.0	-8.0	53.3	45.3	30.2	75.5				n.m.	n.m.	222.4%	-72.9%	-39.7%				
Changes in other assets and liabilities <sup>1</sup>	-233.6	-132.9	-366.6	234.5	-132.1	-313.2	-78.7	-445.3	-187.0	-421.0	-608.0	143.1	-464.9				-20.0%	216.8%	65.9%	-39.0%	252.1%				
Neutralization of gain/loss on disposal of fixed assets and other disposals	-26.8	-12.1	-38.9	-3.7	-42.5	-5.8	-9.4	-48.3	-0.2	-145.5	-145.7	-7.0	-152.7				-99.3%	>1,000%	274.9%	90.2%	258.9%				
Other non-cash income and expenses	2.9	12.2	15.1	-5.3	9.8	11.2	5.9	21.0	16.5	0.1	16.7	-51.3	-34.6				480.4%	-98.8%	10.9%	869.1%	n.m.				
<b>Operating Cash Flow</b>	<b>840.0</b>	<b>852.4</b>	<b>1,692.4</b>	<b>1,551.7</b>	<b>3,244.1</b>	<b>1,015.0</b>	<b>2,566.8</b>	<b>4,259.1</b>	<b>852.7</b>	<b>622.4</b>	<b>1,475.2</b>	<b>1,255.4</b>	<b>2,730.6</b>				<b>1.5%</b>	<b>-27.0%</b>	<b>-12.8%</b>	<b>-19.1%</b>	<b>-15.8%</b>				
thereof: from discontinued operations	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0				n.m.	n.m.	n.m.	n.m.	n.m.				
Payments for investments in intangible assets	-67.9	-52.0	-119.9	-89.2	-209.2	-66.3	-155.6	-275.5	-79.0	-30.9	-109.9	-33.7	-143.5				16.3%	-40.6%	-8.3%	-62.3%	-31.4%				
Payments from the disposal of intangible assets	20.6	4.8	25.4	10.1	35.4	2.3	12.4	37.7	4.4	125.8	130.2	4.9	135.0				-78.8%	>1,000%	413.3%	-51.6%	281.4%				
Payments for investments in property, plant and equipment	-430.5	-246.0	-676.5	-388.5	-1,065.0	-466.4	-854.9	-1,531.4	-572.3	-295.6	-867.9	-428.4	-1,296.3				32.9%	20.2%	28.3%	10.3%	21.7%				
Payments from the disposal of property, plant and equipment	17.1	-7.2	9.9	3.9	13.8	7.1	11.0	20.9	10.1	3.3	13.4	4.2	17.6				-40.7%	n.m.	35.0%	8.8%	27.6%				
Payments for acquisitions less acquired cash and cash equivalents (net)	-694.8	0.0	-694.8	-0.7	-695.5	-158.2	-159.0	-853.8	0.1	0.1	0.1	-9.4	-9.3				n.m.	n.m.	n.m.	>1,000%	-98.7%				
Payments from other divestments	3.7	0.5	4.2	0.1	4.3	-0.1	0.1	4.2	-0.1	-0.2	-0.2	0.0	-0.2				n.m.	n.m.	n.m.	n.m.	n.m.				
Payments for investments in financial assets	-24.4	-23.2	-47.6	-168.7	-216.3	-148.1	-316.8	-364.4	-21.9	-12.2	-34.1	-58.8	-92.9				-10.3%	-47.5%	-28.4%	-65.1%	-57.1%				
Proceeds from the disposal of other financial assets	86.8	37.5	124.3	11.2	135.6	83.9	95.2	219.5	224.5	42.9	267.5	167.0	434.4				158.5%	14.5%	115.1%	>1,000%	220.5%				
Payments for the acquisition of non-financial assets	-100.0	-500.0	-600.0	0.0	-600.0	0.0	0.0	-600.0	-867.0	-1,207.2	-2,104.2	-595.0	-2,699.2				797.0%	141.4%	250.7%	n.m.	349.9%				
Proceeds from the disposal of non-financial assets	100.0	0.0	100.0	0.0	100.0	500.0	500.0	600.0	100.0	1,514.2	1,614.2	598.8	2,213.0				0.0%	n.m.	>1,000%	n.m.	>1,000%				
<b>Investing Cash Flow</b>	<b>-1,089.4</b>	<b>-785.7</b>	<b>-1,875.1</b>	<b>-621.9</b>	<b>-2,496.9</b>	<b>-245.8</b>	<b>-867.6</b>	<b>-2,742.7</b>	<b>-1,231.1</b>	<b>140.2</b>	<b>-1,091.0</b>	<b>-350.3</b>	<b>-1,441.3</b>				<b>13.0%</b>	<b>n.m.</b>	<b>-41.8%</b>	<b>-43.7%</b>	<b>-42.3%</b>				
thereof: from discontinued operations	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0				n.m.	n.m.	n.m.	n.m.	n.m.				
Dividend payments to Merck KGaA shareholders	0.0	-239.1	-239.1	0.0	-239.1	0.0	0.0	-239.1	0.0	-284.3	-284.3	0.0	-284.3				n.m.	18.9%	18.9%	n.m.	18.9%				
Dividend payments to non-controlling interests	-9.6	-1.6	-11.2	0.0	-11.2	-0.3	-0.3	-11.5	0.0	-10.3	-10.3	-0.3	-10.6				-100.0%	546.4%	-8.0%	>1,000%	-5.2%				
Profit withdrawal by E.Merck KG	-90.5	-625.6	-716.1	0.0	-716.1	0.0	0.0	-716.1	-90.4	-777.6	-868.0	0.0	-868.0				-0.2%	24.3%	21.2%	n.m.	21.2%				
Changes in financial liabilities to E. Merck KG and E. Merck Beteiligungen KG	-406.0	976.7	570.7	-104.7	466.0	-442.7	-547.4	23.3	-0.8	697.8	697.1	-100.0	597.1				-99.8%	-28.5%	22.1%	-4.5%	28.1%				
Other changes in net equity	0.3	-0.3	0.0	-0.1	-0.2	0.2	0.1	0.1	0.0	0.0	0.0	0.1	0.1				n.m.	n.m.	n.m.	n.m.	n.m.				
Changes in current and non-current financial liabilities	190.9	57.1	247.9	-804.4	-556.4	-55.3	-859.7	-611.7	215.6	-206.0	9.7	-202.2	-192.5				13.0%	n.m.	-96.1%	-74.9%	-65.4%				
Other changes from financing activities	0.0	0.1	0.0	0.1	0.1	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0				-61.2%	n.m.	n.m.	-86.9%	n.m.				
<b>Financing Cash Flow</b>	<b>-315.0</b>	<b>167.2</b>	<b>-147.8</b>	<b>-909.1</b>	<b>-1,056.9</b>	<b>-498.1</b>	<b>-1,407.2</b>	<b>-1,555.0</b>	<b>124.5</b>	<b>-580.4</b>	<b>-455.9</b>	<b>-302.4</b>	<b>-758.3</b>				<b>n.m.</b>	<b>n.m.</b>	<b>208.5%</b>	<b>-66.7%</b>	<b>-28.3%</b>				
thereof: from discontinued operations	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0				n.m.	n.m.	n.m.	n.m.	n.m.				
<b>Changes in cash and cash equivalents</b>	<b>-564.3</b>	<b>233.9</b>	<b>-330.5</b>	<b>20.8</b>	<b>-309.7</b>	<b>271.1</b>	<b>291.9</b>	<b>-38.6</b>	<b>-254.0</b>	<b>182.2</b>	<b>-71.7</b>	<b>602.7</b>	<b>530.9</b>				<b>-55.0%</b>	<b>-22.1%</b>	<b>-78.3%</b>	<b>&gt;1,000%</b>	<b>n.m.</b>				
Changes in cash and cash equivalents due to currency translation	3.5	7.3	10.8	4.1	14.9	-21.7	-17.7	-6.9	-15.7	-5.3	-21.1	1.7	-19.3				n.m.	n.m.	n.m.	-57.7%	n.m.				
Cash and cash equivalents as of January 1st	1,899.3	0.0	1,899.3	0.0	1,899.3	0.0	0.0	1,899.3	1,853.8	0.0	1,853.8	0.0	1,853.8				-2.4%	-100.0%	-2.4%	-100.0%	-2.4%				
<b>Cash and cash equivalents</b>	<b>1,338.5</b>	<b>241.1</b>	<b>1,579.6</b>	<b>24.9</b>	<b>1,604.4</b>	<b>249.4</b>	<b>274.2</b>	<b>1,853.8</b>	<b>1,584.1</b>	<b>176.9</b>	<b>1,761.0</b>	<b>604.4</b>	<b>2,365.4</b>				<b>18.4%</b>	<b>-26.6%</b>	<b>11.5%</b>	<b>&gt;1,000%</b>	<b>47.4%</b>				
Changes in cash and cash equivalents due to change in scope of consolidation	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0				n.m.	n.m.	n.m.	n.m.	n.m.				

<sup>1</sup> As of January 1, 2023, the tranche of the Group Long-Term Incentive Plan to be paid out in the months following the balance sheet date is disclosed under other current non-financial liabilities and no longer under current provisions for employee benefits. For better comparability, the previous year's figures have been adjusted.

Due to rounding the sum of individual values may not add up to totals presented.

**Balance Sheet Merck KGaA, Darmstadt, Germany**
**Group**

€ million

	2022				2023				Shares of Totals				Shares of Totals			
	31.mar	30.cze	30.wrz	31. Dez	31.mar	30.cze	30.wrz	31.gru	31.mar	30.cze	30.wrz	31. Dez	31.mar	30.cze	30.wrz	31.gru
<b>Non-current assets</b>	<b>35,149.3</b>	<b>36,301.2</b>	<b>37,990.0</b>	<b>36,334.3</b>	<b>35,686.3</b>	<b>35,763.3</b>	<b>36,339.9</b>		76.0%	74.5%	74.6%	74.9%	73.4%	73.3%	72.8%	
Goodwill <sup>1</sup>	17,760.8	18,573.4	19,534.1	18,388.9	18,077.4	18,102.2	18,466.3		38.4%	38.1%	38.4%	37.9%	37.2%	37.1%	37.0%	
Other intangible assets <sup>1</sup>	7,549.5	7,861.8	8,079.8	7,335.4	6,953.8	6,765.2	6,716.5		16.3%	16.1%	15.9%	15.1%	14.3%	13.9%	13.5%	
Property, plant and equipment <sup>1</sup>	7,302.9	7,573.4	7,945.6	8,204.3	8,217.9	8,393.4	8,719.2		15.8%	15.5%	15.6%	16.9%	16.9%	17.2%	17.5%	
Investments accounted for using the equity method	2.8	3.0	3.1	2.9	2.9	2.9	3.0		0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	
Other non-current receivables	24.5	25.7	28.1	27.1	23.9	23.2	24.4		0.1%	0.1%	0.1%	0.1%	0.0%	0.0%	0.0%	
Other non-current financial assets	902.3	901.9	961.7	957.1	958.9	1,040.9	989.8		2.0%	1.9%	1.9%	2.0%	2.0%	2.1%	2.0%	
Other non-current non-financial assets	104.8	99.5	104.1	99.1	99.6	88.1	96.3		0.2%	0.2%	0.2%	0.2%	0.2%	0.2%	0.2%	
Non-current income tax receivables	9.8	9.7	9.4	9.8	9.3	9.2	9.3		0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	
Deferred tax assets	1,492.0	1,252.9	1,324.0	1,309.6	1,342.5	1,338.2	1,315.1		3.2%	2.6%	2.6%	2.7%	2.8%	2.7%	2.6%	
<b>Current assets</b>	<b>11,085.3</b>	<b>12,415.9</b>	<b>12,943.1</b>	<b>12,200.9</b>	<b>12,950.7</b>	<b>13,018.7</b>	<b>13,566.4</b>		24.0%	25.5%	25.4%	25.1%	26.6%	26.7%	27.2%	
Inventories	4,142.8	4,473.7	4,859.9	4,632.1	4,889.6	4,995.8	4,971.1		9.0%	9.2%	9.5%	9.5%	10.1%	10.2%	10.0%	
Trade and other current receivables	4,138.4	4,413.7	4,346.3	4,113.6	4,269.8	4,209.8	4,195.1		9.0%	9.1%	8.5%	8.5%	8.8%	8.6%	8.4%	
Contract assets	207.0	156.1	137.2	128.4	132.6	126.5	122.1		0.4%	0.3%	0.3%	0.3%	0.3%	0.3%	0.2%	
Other current financial assets	105.9	133.5	347.1	321.3	136.8	166.3	218.3		0.2%	0.3%	0.7%	0.7%	0.3%	0.3%	0.4%	
Other current non-financial assets	792.8	1,362.5	1,335.0	705.4	1,515.8	1,250.0	1,140.2		1.7%	2.8%	2.6%	1.5%	3.1%	2.6%	2.3%	
Current income tax receivables	359.9	297.0	313.2	446.3	421.9	509.2	554.2		0.8%	0.6%	0.6%	0.9%	0.9%	1.0%	1.1%	
Cash and cash equivalents	1,338.5	1,579.6	1,604.4	1,853.8	1,584.1	1,761.0	2,365.4		2.9%	3.2%	3.2%	3.8%	3.3%	3.6%	4.7%	
Assets held for sale	0.0	0.0	0.0	0.0	0.0	0.0	0.0		0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	
<b>Total assets</b>	<b>46,234.6</b>	<b>48,717.2</b>	<b>50,933.1</b>	<b>48,535.2</b>	<b>48,637.0</b>	<b>48,781.9</b>	<b>49,906.2</b>		100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	
<b>Total equity</b>	<b>22,990.1</b>	<b>26,028.7</b>	<b>28,337.0</b>	<b>26,005.42</b>	<b>26,230.0</b>	<b>26,771.9</b>	<b>28,294.5</b>		49.7%	53.4%	55.6%	53.6%	53.9%	54.9%	56.7%	
Equity capital	565.2	565.2	565.2	565.2	565.2	565.2	565.2		1.2%	1.2%	1.1%	1.2%	1.2%	1.2%	1.1%	
Capital reserves	3,813.7	3,813.7	3,813.7	3,813.73	3,813.7	3,813.7	3,813.7		8.2%	7.8%	7.5%	7.9%	7.8%	7.8%	7.6%	
Retained earnings	16,450.0	18,014.6	18,825.1	18,462.87	19,250.0	19,760.5	20,710.7		35.6%	37.0%	37.0%	38.0%	39.6%	40.5%	41.5%	
Gain/losses recognized in equity	2,090.5	3,561.4	5,056.3	3,085.59	2,520.3	2,561.2	3,132.2		4.5%	7.3%	9.9%	6.4%	5.2%	5.3%	6.3%	
Non-controlling interest	70.7	73.7	76.7	77.99	80.7	71.3	72.7		0.2%	0.2%	0.2%	0.2%	0.2%	0.1%	0.1%	
<b>Non-current liabilities</b>	<b>13,037.5</b>	<b>12,970.7</b>	<b>13,184.4</b>	<b>13,015.5</b>	<b>12,850.8</b>	<b>13,163.9</b>	<b>12,926.3</b>		28.2%	26.6%	25.9%	26.8%	26.4%	27.0%	25.9%	
Non-current provisions for employee benefits	2,879.1	1,666.1	1,954.9	2,030.0	1,965.3	1,994.5	1,773.6		6.2%	3.4%	3.8%	4.2%	4.0%	4.1%	3.6%	
Other non-current provisions	279.1	265.2	300.3	299.4	307.0	294.1	276.0		0.6%	0.5%	0.6%	0.6%	0.6%	0.6%	0.6%	
Non-current financial debt	8,285.8	9,385.4	9,265.6	9,200.4	9,159.3	9,495.4	9,540.5		17.9%	19.3%	18.2%	19.0%	18.8%	19.5%	19.1%	
Other non-current financial liabilities <sup>2</sup>	143.2	148.7	150.2	141.4	142.4	141.3	142.8		0.3%	0.3%	0.3%	0.3%	0.3%	0.3%	0.3%	
Other non-current non-financial liabilities <sup>2</sup>	20.4	21.8	23.1	19.4	19.3	19.0	18.2		0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	
Non-current income tax liabilities	40.7	41.3	40.9	38.1	38.0	37.5	41.0		0.1%	0.1%	0.1%	0.1%	0.1%	0.1%	0.1%	
Deferred tax liabilities <sup>1</sup>	1,389.2	1,442.1	1,449.4	1,286.8	1,219.4	1,182.1	1,134.3		3.0%	3.0%	2.8%	2.7%	2.5%	2.4%	2.3%	
<b>Current liabilities</b>	<b>10,206.9</b>	<b>9,717.8</b>	<b>9,411.8</b>	<b>9,514.3</b>	<b>9,556.2</b>	<b>8,846.1</b>	<b>8,685.4</b>		22.1%	19.9%	18.5%	19.6%	19.6%	18.1%	17.4%	
Current provisions for employee benefits <sup>3</sup>	96.1	181.8	207.4	80.6	131.6	105.9	124.4		0.2%	0.4%	0.4%	0.2%	0.3%	0.2%	0.2%	
Other current provisions	372.0	341.5	355.0	372.4	378.8	448.1	469.0		0.8%	0.7%	0.7%	0.8%	0.8%	0.9%	0.9%	
Current financial debt	2,344.9	2,417.7	1,784.5	1,227.9	1,484.9	1,690.1	1,415.7		5.1%	5.0%	3.5%	2.5%	3.1%	3.5%	2.8%	
Other current financial liabilities <sup>2</sup>	930.9	419.3	471.0	1,153.2	1,017.3	259.1	241.8		2.0%	0.9%	0.9%	2.4%	2.1%	0.5%	0.5%	
Trade and other current payables <sup>1</sup>	2,356.3	2,456.3	2,445.1	2,498.7	2,326.1	2,402.7	2,243.8		5.1%	5.0%	4.8%	5.1%	4.8%	4.9%	4.5%	
Refund liabilities	873.2	972.1	968.1	912.3	947.1	963.1	990.0		1.9%	2.0%	1.9%	1.9%	1.9%	2.0%	2.0%	
Current income tax liabilities	1,465.8	1,430.0	1,520.2	1,483.4	1,461.4	1,487.8	1,580.7		3.2%	2.9%	3.0%	3.1%	3.0%	3.0%	3.2%	
Other current non-financial liabilities <sup>2,3</sup>	1,767.8	1,499.0	1,660.5	1,785.8	1,809.1	1,489.4	1,620.1		3.8%	3.1%	3.3%	3.7%	3.7%	3.1%	3.2%	
Liabilities included in disposal groups classified as held for sale	0.0	0.0	0.0	0.0	0.0	0.0	0.0		0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	
<b>Total liabilities and stockholders' equity</b>	<b>46,234.6</b>	<b>48,717.2</b>	<b>50,933.1</b>	<b>48,535.2</b>	<b>48,637.0</b>	<b>48,781.9</b>	<b>49,906.2</b>		100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	

	2022				2023				Shares of Totals				Shares of Totals			
	31.mar	30.cze	30.wrz	31. Dez	31.mar	30.cze	30.wrz	31.gru	31.mar	30.cze	30.wrz	31. Dez	31.mar	30.cze	30.wrz	31.gru
Financial debt	10,630.7	11,803.1	11,050.0	10,428.3	10,644.2	11,185.5	10,956.2		23.0%	24.2%	21.7%	21.5%	21.9%	22.9%	22.0%	
Net financial debt	9,228.4	10,165.2	9,214.6	8,327.6	8,991.9	9,354.9	8,426.5		20.0%	20.9%	18.1%	17.2%	18.5%	19.2%	16.9%	
Additions to Property, plant and equipment (excl. Leasing) <sup>4</sup>	209.1	488.0	858.3	1,526.9	297.9	669.6	1,108.0		n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	

Due to rounding the sum of individual values may not add up to totals presented.

<sup>1</sup> Previous-year figures have been adjusted owing to the finalization of the purchase price allocation in connection with the acquisitions of the chemical business of Mecaro Co. Ltd., Korea, trading as M Chemicals Inc., Korea, as well as Erbi Biosystems Inc., USA.

<sup>2</sup> As of January 1, 2023, wage- and salary-related liabilities are disclosed under other non-financial liabilities instead of under other financial liabilities as in the past.

For better comparability, the previous year's figures have been adjusted.

<sup>3</sup> As of January 1, 2023, the tranche of the Group Long-Term Incentive Plan to be paid out in the months following the balance sheet date is disclosed under other current non-financial liabilities and no longer under current provisions for employee benefits. For better comparability, the previous year's figures have been adjusted.

<sup>4</sup> Figures are year-to-date figures from January 1st until stated end date.